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Editorial on the research topic
C-Reactive Protein in Age-Related Disorders
Over the last decade, native pentameric C-reactive protein (pCRP), and its biologically active
dissociated monomer monomeric CRP (mCRP), have hit the headlines as it has become realized
that they may not play such a passive role in disease development and pathophysiology as was once
thought. In this series we have composed the thoughts and research of the most eminent scientists
in the field of CRP-research in a mixture of original articles and reviews on the subject with a view
to creation of an archive of current knowledge and understanding.
Both acute and chronic inflammation are hallmarks of potential injury and illness and are
critical pathophysiological fingerprints of major disease development such as in cardiovascular
disease, diabetes, obesity, and cancer (Gupta et al.). Circulating levels of pCRP have been used in
conjunction with other biomarkers to measure accurately systemic levels of inflammation but too
often only poorly, the prediction of future pathobiological events or consequences of the acute
immune response. As our understanding of the biological importance of mCRP has increased,
so has the suggestion that measurement of its circulating levels associated with microparticles,
macrophages, and platelets of plasma, in patients with both acute and chronic inflammatory
conditions could represent a much more accurate event predictor. Here, for the first time,
Zhang et al. have produced a quantifiable ELISA assay accurately measuring mCRP levels in
plasma. Furthermore, they went on to test this on a small cohort of patients with skin-related
immune disorders showing that mCRP indeed predicted the course of illness far better than
pCRP measurements. In acute coronary syndromes, autoimmune diseases (e.g., Lupus, giant cell
arteritis) and possibly even some solid tumors, measurements of plasma mCRP may prove to be a
significantly better prognostic indicator (1, 2).
Recent publications have highlighted important novel biological mechanisms associated with
both native pCRP andmCRP signaling and pathophysiological action. For example, the work ofWu
et al. (3) and Thiele et al. on understanding CRP conformational changes associated with induction
of inflammation, and lipid binding details to apoptotic cell membranes by Alnaas et al. (4). In
this series, we have included a group of focussed reviews relating the current state of knowledge
of the role of CRP in major disease progression. Articles by Molins et al. Chirco and Potempa
and Fernandez-Robredo et al. have discussed local inflammation and immune activation in age-
related macular degeneration (AMD), a major cause of blindness, highlighting its pathogenic role
via activation of complement; and identifying an association of A69S SNIP with high levels of CRP
and degeneration in wet AMD.
Other reviews have discussed the impact of cellular and tissue deposition of mCRP on
atherosclerotic plaque development, dementia and AMD (McFadyen et al.), and others the
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inflammatory links to diabetes and Parkinson’s (Luan and Yao).
Previously cited work by Strang et al. (5) and Slevin et al. (6)
have already provided strong evidence of a possible causative
involvement of mCRP in development of beta-amyloid plaques
and neurodegeneration-associated cognitive impairment linked
to Alzheimer’s and dementia, suggesting that CRP manipulation
could represent a future therapeutic target for helping to protect
against development of these conditions.
Sproston and Ashworth discussed details of a novel
mechanism for a role of CRP in response to infection,
recruitment of leukocytes (also shown by Thiele et al. (7)
in an ischemia-reperfusion injury model) and induction of nitric
oxide (NO) (mCRP), following this up with a detailed original
article measuring CRP associated changes in NO and iNOS using
a monocyte-macrophage model of aging and inflammation.
Additional reviews in our series have focussed on the ability of
mCRP to activate endothelial cells, stimulating angiogenesis,
increase plaque instability in coronary artery disease and
potentially catalyze thrombosis leading to myocardial infarction
(Badimon et al.). Di Napoli et al.. also discussed the utility
of CRP as a biomarker for, and predictor of both long and
short-term outcomes in intracerebral hemorrhage. Release of
CRP and possible accumulation of mCRP in the brain after
stroke, could contribute significantly to inflammation during the
acute phase, and neurodegeneration thereafter (8) and hence
further investigation of its role in these processes and the others
described above is warranted.
Finally, we include in this series a group of articles focussed on
detailing distinct novel biological properties of CRP. Sudhakar
et al. showed increased CRP in non-morbidly obese individuals
and preferred mCRP binding to the leptin receptor in human
plasma and this could link to low-grade systemic infection
on over-weight individuals. Jia et al. demonstrated binding of
mCRP to receptor activator of NF-κB associated with blocking
osteoclast differentiation with potential protective action in joint
inflammation associated with rheumatoid arthritis. On the other
hand Jimenez et al. showed that CRP may also play a role in
the maintenance of peripheral T cell tolerance as they showed
the ability of CRP to suppress development, maturation, and
function of dendritic cells. Interest has arisen with regard to the
potential interaction between CRP and nicotinic/acetylcholine
receptors. CRP is known to affect innate immunity operating
through the nicotinic acetylcholine receptors and here, Richter
et al. (9) showed that pCRP associated with phosphocholine,
could block macrophage-induced cytokine release potentially
protecting trauma-associated injuries in vivo. In contrast, mCRP
potently stimulates macrophage-associated inflammation, and
further work detailed in this series showed that acetylcholine
inclusion, within an in vitro model of inflammation, could
effectively block mCRP-induced production of tumor necrosis
factor-alpha (10).
A detailed analysis of crystal binding structure of mCRP by
Caprio et al. concluded that various phospholipase A2 inhibitors
might have therapeutic potential to block the early interaction of
the molecule at the cell membrane thus negating activation of
harmful biological effects. Future work could focus on effective
prevention of mCRP binding to activated cell surfaces; or
even more excitingly, either systemically or in a targeted form,
blocking the primary pCRP-mCRP dissociation especially during
acute inflammatory conditions.
In conclusion, the series provides an encyclopedia of current
knowledge within the field of CRP research, it highlights new
findings and major links to critical disease processes. It defines
clear and opposing actions of the pentameric protein when
compared with the dissociated monomer, and it expresses
the complexity of cell and tissue specific interactions of this
highly conserved molecule. Publications within this topic will
undoubtedly increase over the coming years and we hope this
collection will serve as a valuable reference for this future
investigation.
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